- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Immunization registry.
Displaying page 1 of 1.
EudraCT Number: 2021-003953-43 | Sponsor Protocol Number: VAC31518COV3005 | Start Date*: 2021-11-29 | ||||||||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older | ||||||||||||||||||
Medical condition: Healthy Volunteers (Prevention of COVID-19 and influenza) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-004181-37 | Sponsor Protocol Number: B9371039 | Start Date*: 2023-02-03 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER | ||
Medical condition: Active immunization to prevent tick borne encephalitis (TBE) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-003194-33 | Sponsor Protocol Number: VAC18193RSV2002 | Start Date*: 2017-10-03 |
Sponsor Name:Janssen Vaccines and Prevention B.V. | ||
Full Title: An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infe... | ||
Medical condition: Prophylactic respiratory syncytial virus (RSV) vaccine. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005154-57 | Sponsor Protocol Number: CACZ885D2307E1 | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001653-32 | Sponsor Protocol Number: C0168IBD4020 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Janssen Scientific Affairs, LLC | |||||||||||||
Full Title: A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with inflammatory Bowel Disease | |||||||||||||
Medical condition: Inflammatory Bowel Diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003666-13 | Sponsor Protocol Number: VAC89220HPX3002 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1... | |||||||||||||
Medical condition: Prevention of HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015019-42 | Sponsor Protocol Number: CNTO148JIA3001 | Start Date*: 2011-05-10 | |||||||||||
Sponsor Name:Janssen Biologics B.V. | |||||||||||||
Full Title: A Multicenter, Double Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects with Active Polyarticular Course Juvenile Idiopathic Arthritis ... | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis (JIA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) BE (Completed) LT (Prematurely Ended) FI (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000681-10 | Sponsor Protocol Number: I1F-MC-RHCG | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes ... | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002479-20 | Sponsor Protocol Number: 80202135MYG2001 | Start Date*: 2022-09-29 | |||||||||||
Sponsor Name:Janssen-Cilag Invernational N.V. | |||||||||||||
Full Title: An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to less than 18 years with Generalized Myasthe... | |||||||||||||
Medical condition: Myasthenia gravis (MG) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) Outside EU/EEA PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
